Essential CNS Drug Development. Edited by Amir Kalali ... [Et Al.] PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Essential CNS Drug Development. Edited by Amir Kalali ... [Et Al.] PDF full book. Access full book title Essential CNS Drug Development. Edited by Amir Kalali ... [Et Al.] by Amir Kalali. Download full books in PDF and EPUB format.
![Essential CNS Drug Development. Edited by Amir Kalali ... [Et Al.] PDF](https://books.google.com/books/content/images/frontcover/XdPUoQEACAAJ?fife=w150-h200)
Author: Amir Kalali
Publisher:
ISBN: 9781139568760
Category : Central nervous system stimulants
Languages : en
Pages : 228
Get Book Here
Book Description
Presents the complicated process of CNS drug development in a way that is engaging and informative for professionals and students.
![Essential CNS Drug Development. Edited by Amir Kalali ... [Et Al.] PDF](https://books.google.com/books/content/images/frontcover/XdPUoQEACAAJ?fife=w80-h100)
Author: Amir Kalali
Publisher:
ISBN: 9781139568760
Category : Central nervous system stimulants
Languages : en
Pages : 228
Get Book Here
Book Description
Presents the complicated process of CNS drug development in a way that is engaging and informative for professionals and students.
Author: Amir Kalali
Publisher: Cambridge University Press
ISBN: 1139576526
Category : Medical
Languages : en
Pages : 219
Get Book Here
Book Description
Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians.
Author: Amir Kalali
Publisher: Cambridge University Press
ISBN: 0521766060
Category : Medical
Languages : en
Pages : 219
Get Book Here
Book Description
Presents the complicated process of CNS drug development in a way that is engaging and informative for professionals and students.
Author: George G. Nomikos
Publisher: Academic Press
ISBN: 0128031646
Category : Medical
Languages : en
Pages : 460
Get Book Here
Book Description
Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans. - Includes comprehensive coverage of biomarker tools and the role of personalized medicine in CNS drug development - Discusses strategies for drug development for a full range of CNS indications, with particular attention to neuropsychiatric and neurocognitive disorders - Includes chapters written by international experts from industry and academia
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309163358
Category : Medical
Languages : en
Pages : 151
Get Book Here
Book Description
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise.
Author:
Publisher:
ISBN:
Category : Attention-deficit hyperactivity disorder
Languages : en
Pages : 48
Get Book Here
Book Description
Author: Lloyd Johnston
Publisher:
ISBN:
Category : Adulthood
Languages : en
Pages : 712
Get Book Here
Book Description
NIH publication ; no. 06-5883.
Author: Tonmoy Sharma
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 382
Get Book Here
Book Description
Although it has been known for 100 years that cognitive functioning is impaired in schizophrenia, the implications of this impairment have only recently been clearly understood. While in the past, cognitive deficits were thought to be the result of other aspects of the illness, such as poor co-operation, or as a result of the treatment of the illness, it is now known that these factors exert only a very minor influence on cognitive deficit. This book, with contributions from the major international names in the field, reviews the most recent research on the impairment of cognitive functioning in schizophrenia, covering: what it is, how wide-ranging it can be, what the clinical implications are, and how it can be treated? A detailed insight into cognitive deficit is the key to understanding why previous treatments have failed, and the key by which new treatments may change this terrible illness, treatments significantly more effective than earlier interventions.
Author: Per Bech
Publisher: Springer Science & Business Media
ISBN: 3642753736
Category : Medical
Languages : en
Pages : 139
Get Book Here
Book Description
The European College of Neuropsychopharmacology (ECNP) is a scientific and educational association which represents a variety of disciplines. The first ECNP congress took place in Copenhagen, May 1985, where a working group of European scientists within the field of psychopharmacology was elected to prepare a constituent ECNP congress in Brussels, 1987. Among the most active members of this group was Max Hamilton. At the second ECNP congress in Brussels Max Hamilton was elected as the first honorary member of the ECNP. When we received the message of his death we decided at once to arrange a Max Hamilton memorial symposium at the third ECNP congress, May 1989, in Gothenburg, Sweden. This monograph contains the proceedings of the Max Hamilton symposium which was chaired by the editors. The opening lecture of the third ECNP congress was a Max Hamilton lecture: "A life devoted to science in psychiatry" which was presented by Sir Martin Roth. It seemed obvious to include Sir Martin's lecture as the opening article of this monograph. Although G .E. Berrios was unable to participate in the ECNP congress we have found it logical to include his manuscript on "The Hamilton Depression Scale and the Numerical Description of the Symptoms of Depression" as another personal contribution to Max Hamilton and his rating scales.
Author: Peter Haddad
Publisher: Oxford University Press
ISBN: 0191045780
Category : Medical
Languages : en
Pages : 266
Get Book Here
Book Description
Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.
